· Guests Online: 5
· Members Online: 0
· Total Members: 339
· Newest Member: mohamed bakri
|
<< February 2012 >>
| Mo |
Tu |
We |
Th |
Fr |
Sa |
Su |
| |
|
1 |
2 |
3 |
4 |
5 |
| 6 |
7 |
8 |
9 |
10 |
11 |
12 |
| 13 |
14 |
15 |
16 |
17 |
18 |
19 |
| 20 |
21 |
22 |
23 |
24 |
25 |
26 |
| 27 |
28 |
29 |
|
|
|
|
|
|
ICU Scores: New Simplified Acute Physiology Score (SAPS II)
JAMA 1994 May 4;271(17):1321
Le Gall JR, Lemeshow S, Saulnier F.
Faculty of Medicine Lariboisiere-Saint-Louis, Paris, France.
OBJECTIVE--To develop and validate a new Simplified Acute Physiology Score, the SAPS II, from a large sample of surgical and medical patients, and to provide a method to convert the score to a probability of hospital mortality. DESIGN AND SETTING--The SAPS II and the probability of hospital mortality were developed and validated using data from consecutive admissions to 137 adult medical and/or surgical intensive care units in 12 countries. PATIENTS--The 13,152 patients were randomly divided into developmental (65%) and validation (35%) samples. Patients younger than 18 years, burn patients, coronary care patients, and cardiac surgery patients were excluded. OUTCOME MEASURE--Vital status at hospital discharge. RESULTS--The SAPS II includes only 17 variables: 12 physiology variables, age, type of admission (scheduled surgical, unscheduled surgical, or medical), and three underlying disease variables (acquired immunodeficiency syndrome, metastatic cancer, and hematologic malignancy). Goodness-of-fit tests indicated that the model performed well in the developmental sample and validated well in an independent sample of patients (P = .883 and P = .104 in the developmental and validation samples, respectively). The area under the receiver operating characteristic curve was 0.88 in the developmental sample and 0.86 in the validation sample. CONCLUSION--The SAPS II, based on a large international sample of patients, provides an estimate of the risk of death without having to specify a primary diagnosis. This is a starting point for future evaluation of the efficiency of intensive care units
Up to SAPS II
| Chronic Health Conditions |
|
AIDS
|
HIV positive with clinical complications as pneumocystis carinii pneumonia, Kaposi's sarcoma, Lymphoma, tuberculosis or toxoplasma infection |
| Hematologic malignancy |
lymphoma, acute leukemia, or multiple myeloma |
| Metastatic cancer |
proven metastasis by surgery, C.T. scan or any other method |
Up to SAPS II
|
|
By making a donation to the Middle East Critical Care Assembly, you’ll know that you have been instrumental in the education of not only the current medical professionals but also those still in training. Your contribution will help to facilitate professional education and will assist the Assembly in its efforts to provide quality and innovative programs for the current and next generation of medical professionals |
| |
|
|
